Status of PSMA-targeted radioligand therapy in prostate cancer: current data and future trials
Metastatic prostate cancer continues to be an incurable disease. Despite all the novel
therapies approved in the past two decades, overall patient outcomes remain relatively poor …
therapies approved in the past two decades, overall patient outcomes remain relatively poor …
Efficacy and Safety of 225Ac-PSMA-617-Targeted Alpha Therapy in Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis
J Ma, L Li, T Liao, W Gong, C Zhang - Frontiers in Oncology, 2022 - frontiersin.org
Objective To conduct a meta-analysis of the efficacy and safety of 225Ac-PSMA-617 in the
treatment of metastatic castration-resistant prostate cancer based on existing clinical …
treatment of metastatic castration-resistant prostate cancer based on existing clinical …
Prostate-specific membrane antigen radioligand therapy using 177Lu-PSMA I&T and 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer …
C Schuchardt, J Zhang, HR Kulkarni… - Journal of Nuclear …, 2022 - Soc Nuclear Med
The objective of this study was to determine the safety, kinetics, and dosimetry of the 177Lu-
labeled prostate-specific membrane antigen (PSMA) small molecules 177Lu-PSMA I&T and …
labeled prostate-specific membrane antigen (PSMA) small molecules 177Lu-PSMA I&T and …
Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study
MM Sathekge, IO Lawal, C Bal, F Bruchertseifer… - The Lancet …, 2024 - thelancet.com
Summary Background Actinium-225 (225 Ac) prostate-specific membrane antigen (PSMA)
radioligand therapy (RLT) is a novel therapy for metastatic castration-resistant prostate …
radioligand therapy (RLT) is a novel therapy for metastatic castration-resistant prostate …
[HTML][HTML] Implications of physics, chemistry and biology for dosimetry calculations using theranostic pairs
Theranostics is an emerging paradigm that combines imaging and therapy in order to
personalize patient treatment. In nuclear medicine, this is achieved by using …
personalize patient treatment. In nuclear medicine, this is achieved by using …
Early molecular imaging response assessment based on determination of total viable tumor burden in [68 Ga] Ga-PSMA-11 PET/CT independently predicts overall …
F Rosar, F Wenner, F Khreish, S Dewes… - European Journal of …, 2022 - Springer
Purpose In patients with metastatic castration-resistant prostate cancer (mCRPC) treated
with prostate-specific membrane antigen-targeted radioligand therapy (PSMA-RLT), the …
with prostate-specific membrane antigen-targeted radioligand therapy (PSMA-RLT), the …
Global experience with PSMA-based alpha therapy in prostate cancer
MM Sathekge, F Bruchertseifer, M Vorster… - European Journal of …, 2021 - Springer
Purpose This review discusses the current state of prostate-specific membrane antigen
(PSMA)-based alpha therapy of metastatic castration-resistant prostate cancer (mCRPC) …
(PSMA)-based alpha therapy of metastatic castration-resistant prostate cancer (mCRPC) …
[HTML][HTML] [161Tb] Tb-PSMA-617 radioligand therapy in patients with mCRPC: preliminary dosimetry results and intra-individual head-to-head comparison to [177Lu] Lu …
A Schaefer-Schuler, C Burgard, A Blickle, S Maus… - Theranostics, 2024 - ncbi.nlm.nih.gov
Rationale: Evaluation of alternative radionuclides for use in prostate-specific membrane
antigen (PSMA)-targeted radioligand therapy (RLT) is currently focusing on 161 Tb, which …
antigen (PSMA)-targeted radioligand therapy (RLT) is currently focusing on 161 Tb, which …
Predictors and real-world use of prostate-specific radioligand therapy: PSMA and beyond
PSMA is a transmembrane protein that is markedly overexpressed in prostate cancer,
making it an excellent target for imaging and treating patients with prostate cancer. Several …
making it an excellent target for imaging and treating patients with prostate cancer. Several …